MemorialCare, a California-based-based not-for-profit, integrated healthcare system, announced on Thursday that its Long Beach Medical Center, Orange Coast Medical Center, and Saddleback Medical Center have received multiple honours in the 2026 Women's Choice Awards.
This year, all MemorialCare hospitals were honoured in 10 different categories representing diverse clinical strengths.
Orange Coast Medical Center was named a Best Hospital for Patient Safety, Heart Care, Cancer Care, Bariatric Surgery, Obstetrics, Women's Services, Orthopedics, and Knee and Hip Replacement.
Saddleback Medical Center received distinctions as a Best Hospital for Patient Safety, Heart Care, Stroke Care, Minimally Invasive Surgery, Obstetrics, Orthopedics, and Knee and Hip Replacement.
Long Beach Medical Center was recognised as a Best Hospital for Heart Care, Stroke Care, and Cancer Care.
Eugene Kim, MD, chief medical officer of MemorialCare, commented: "This acknowledgement demonstrates that women trust us with their health, and that of their families. We honour that trust by providing the highest standard of care through ongoing innovation and high-quality care, while supporting patient empowerment and advocacy."
Insilico Medicine signs multi-year research and development collaboration with Servier
MemorialCare hospitals recognised in 2026 Women's Choice Awards
International Isotopes Inc to change name to Radnostix Inc
Delcath publishes Phase 3 FOCUS subgroup data supporting HEPZATO in metastatic uveal melanoma
Corcept announces receipt of FDA Complete Response letter for relacorilant in hypercortisolism
Sensiva Health names new chief operating officer
HUTCHMED savolitinib NDA for MET-amplified gastric cancer accepted for priority review in China
SOFIE Biosciences reports first patient dosed Phase 3 clinical trial of [18F]FAPI-74
ABL Bio receives upfront payment and equity investment from Eli Lilly
Harbour BioMed and Yantai Lannacheng Biotechnology form collaboration to advance next-gen RDCs
Repare Therapeutics sells RP-3467 asset to Gilead Sciences for up to USD30m
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer